Core Viewpoint - Entera Bio Ltd. is actively participating in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, showcasing its advancements in orally delivered peptides and therapeutic proteins [1][2]. Company Overview - Entera Bio is a clinical-stage company focused on developing tablet treatments for peptide and small protein replacement therapies, addressing significant unmet medical needs [3]. - The company utilizes a proprietary technology platform (N-Tab™) and has a pipeline that includes five first-in-class oral peptide programs [3]. - The most advanced product candidate, EB613, is being developed as the first oral osteoanabolic treatment for post-menopausal women with low bone mineral density (BMD) and high-risk osteoporosis [3]. - A Phase 2 study of EB613 met primary and secondary endpoints, with results published in the Journal for Bone and Mineral Research [3]. - Entera is preparing to initiate a Phase 3 registrational study for EB613 in the second half of 2025, pending FDA qualification of a quantitative treat-to-target BMD endpoint [3]. - Other programs include EB612 for hypoparathyroidism and collaborations with OPKO Health for oral treatments targeting obesity and gastrointestinal conditions [3].
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference